Chemical formula: C₁₇H₂₅N₃O₂S Molecular mass: 335.464 g/mol PubChem compound: 4440
Naratriptan has been shown to be a selective agonist for 5 hydroxytryptamine1 (5-HT1) receptors mediating vascular contraction. This receptor is found predominantly in intracranial (cerebral and dural) blood vessels. Naratriptan is indicated for the acute treatment of migraine attacks with or without aura.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N02CC02 | Naratriptan | N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CC Selective serotonin (5HT1) agonists |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| NARAMIG Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Naratriptan is an active ingredient of these brands:
United States (US)
Australia (AU)
Brazil (BR)Canada (CA)
Estonia (EE)
Finland (FI)
France (FR)
Germany (DE)
Ireland (IE)Israel (IL)
Japan (JP)
Lithuania (LT)
Netherlands (NL)
Romania (RO)
Singapore (SG)
South Africa (ZA)
Spain (ES)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
